Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers have reported the results of the first randomised clinical trial to test a novel strategy. The approach involves waking up and then killing the ‘sleeping’ HIV that is hiding in the body using an experimental approach known as ‘kick and kill’.

Led by Imperial College London, the University of OxfordMRC Clinical Trials Unit at UCL, and the University of Cambridge, the RIVER study aimed to improve on current care by eradicating HIV from the body, which would represent a major step forward in the search for a cure

Read the full article

Similar stories

Côte d’Ivoire becomes first nation to deploy R21 malaria vaccine

Côte d’Ivoire will become the first country to roll-out the new R21/Matrix-M™ vaccine with the first child vaccinated in Abidjan, marking a critical step and historic milestone in the global fight against malaria. 15 African countries are expected to introduce malaria vaccines with Gavi support in 2024, and countries plan to reach around 6.6 million children with the malaria vaccine in 2024 and 2025. The new vaccine has been authorised by Ghana, Nigeria, Burkina Faso and the Central African Republic, and many others are preparing to receive shipments.